Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party. The US-based company received the PRV when its Niemann-Pick disease type C ...

After receiving a rare pediatric disease priority review voucher (PRV) in tandem with Miplyffa’s FDA green light in September, Zevra has locked in a deal to sell the PRV for $150 million.

Because Miplyffa had previously been designated a rare pediatric disease drug, it was grandfathered under the FDA’s Rare Pediatric Disease PRV program, despite it starting to sunset on December ...

Bavarian Nordic has reached an agreement to sell a priority review voucher (PRV) gained from Vimkunya’s approval to an unnamed buyer for $160 million, the Danish company said Wednesday.